Literature DB >> 19537399

Use of thalidomide in the management of three HIV seroreactive children with Kaposi's sarcoma referred for palliative care.

Mary R Bunn1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19537399      PMCID: PMC3345709          DOI: 10.4314/mmj.v20i4.10980

Source DB:  PubMed          Journal:  Malawi Med J        ISSN: 1995-7262            Impact factor:   0.875


× No keyword cloud information.
  7 in total

1.  Growing interest in thalidomide.

Authors:  B Lowell
Journal:  GMHC Treat Issues       Date:  1995-05

Review 2.  Cancer pain relief and palliative care. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1990

3.  S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide.

Authors:  J B Zeldis; B A Williams; S D Thomas; M E Elsayed
Journal:  Clin Ther       Date:  1999-02       Impact factor: 3.393

Review 4.  Thalidomide: current and potential clinical applications.

Authors:  L Calabrese; A B Fleischer
Journal:  Am J Med       Date:  2000-04-15       Impact factor: 4.965

5.  Thalidomide in the treatment of Kaposi's sarcoma.

Authors:  Pietro Rubegni; Paolo Sbano; Giovambattista De Aloe; Maria Laura Flori; Michele Fimiani
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

Review 6.  Recent advances in the treatment of AIDS-related Kaposi's sarcoma.

Authors:  Anna M Cattelan; Marco Trevenzoli; Savina M L Aversa
Journal:  Am J Clin Dermatol       Date:  2002       Impact factor: 7.403

7.  Long term use of thalidomide: safe and effective.

Authors:  A Sharma; V Raina; G Uppal; R Kumar; J Grover
Journal:  Indian J Cancer       Date:  2007 Jul-Sep       Impact factor: 1.224

  7 in total
  1 in total

Review 1.  Advances in the systemic treatment of cutaneous sarcomas.

Authors:  Jason J Luke; Mary Louise Keohan
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.